“Patients who really need to be screened are not getting screened,” says Ram Pathak, MD.
In this video, Ram Pathak, MD, an assistant professor at Mayo Clinic, discusses how the United States Preventative Services Task Force (USPSTF) grade D recommendation against PSA screening has resulted in a disproportionate increase in the incidence of metastatic prostate cancer among minority populations at screening.
At the 2022 AUA Annual Meeting, Pathak shared the abstract, “Racial and ethnic disparities magnified after USPSTF category D recommendation for PSA screening.”
HUMC provides groundbreaking focal therapy for prostate cancer
September 13th 2023The Focal One high intensity focused ultrasound system uses precision sound waves to destroy prostate tumor tissue and spare healthy tissue, reducing the risk of side effects that would lower a patient's quality of life.
2 Clarke Drive
Cranbury, NJ 08512